Lazard Asset Management
CBAY

Lazard Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

Lazard Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-30,345
Closed -$394K – 1132
2018
Q1 		$394K Buy
+30,345
New +$377K ﹤0.01% 789

Other funds holding CBAY

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Lazard Asset Management's CBAY Position: Q2 2018 in Review

Lazard Asset Management sold out of Cymabay Therapeutics (CBAY) in Q2 2018, closing a stake of 30,345 shares — an estimated $394K sold.

Lazard Asset Management first reported a position in CBAY in Q1 2018 and held it in 1 quarter. The position peaked at $394K in Q1 2018. 118 funds tracked by Wall St. Rank hold CBAY as of Q2 2018.

  • Lazard Asset Management reported no remaining Cymabay Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Lazard Asset Management sold 30,345 Cymabay Therapeutics shares in Q2 2018, an estimated $394K.
  • Lazard Asset Management first reported a position in Cymabay Therapeutics in Q1 2018 and held it in 1 quarter.
  • Lazard Asset Management's Cymabay Therapeutics position peaked at $394K in Q1 2018.
  • 118 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2018.

Based on Lazard Asset Management's 13F filing for Q2 2018, filed 13 Aug 2018.